SCHEMBL5046918

SCHEMBL5046918

CCC(C)NC(=O)c1cc(-c2csc(-c3ccccc3Cl)n2)n(CC2CCCO2)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
KMT2A Q03164 4/20 0.47
RECQL P46063 3/20 0.47
BLM P54132 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
KDM4E B2RXH2 1/20 0.47
APAF1 O14727 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MEN1 O00255 2/20 0.43
ALOX15 P16050 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
TNK2 Q07912 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046842 0.89 TNK2 (0.43) ALDH1A1KMT2ARECQLBLML3MBTL1
SCHEMBL5043862 0.89 CNR1 (0.43) ALDH1A1KMT2AKDM4EMAPTHPGD
SCHEMBL5048548 0.88 CDC25A (0.46) ALDH1A1KMT2ARECQLBLML3MBTL1
SCHEMBL5043863 0.87 TNK2 (0.42) ALDH1A1KMT2ARECQLBLML3MBTL1
SCHEMBL5047024 0.85 ALDH1A1 (0.46) ALDH1A1KMT2ARECQLBLMKDM4E
SCHEMBL5043937 0.84 CDC25A (0.59) ALDH1A1KMT2ARECQLBLML3MBTL1
SCHEMBL5047599 0.84 IDH1 (0.44) ALDH1A1KMT2AKDM4EMAPTHPGD
SCHEMBL5047659 0.84 ALDH1A1 (0.42) ALDH1A1KMT2ARECQLBLML3MBTL1
SCHEMBL5043824 0.83 MEN1 (0.43) ALDH1A1KMT2AKDM4EPOLBMAPT
SCHEMBL5044425 0.82 RAB9A (0.43) ALDH1A1KMT2AL3MBTL1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R ALDH1A1 959/4885KMT2A 4280/4885RECQL 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.